BioLife Solutions, Inc.
BLFS
NASDAQ·Healthcare·Medical - Instruments & Supplies·Mkt cap $1.7B
$35.25
▼ -0.79%
P/E
33.76
Mkt Cap
$1.7B
52-Wk Range
$17.86–$38.10
52-Week Range
$17.86 - $38.10
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 34.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Proprietary biopreservation formulations with patent protection and regulatory validation
- Integrated ecosystem of complementary products creating customer lock-in and switching costs
- Established relationships with leading cell and gene therapy manufacturers and research institutions
- Cloud-connected smart logistics technology providing real-time monitoring and data analytics
- Decades of industry expertise and scientific credibility since 1987 founding
Bear Case
2 risks
- Above-average volatility (beta 1.9).
- Growth premium of 2.9x vs Medical Devices peers. Elevated but may be justified by growth trajectory.
Growth
Moderate growth ahead
Steady revenue growth (17% YoY)
Value
Growth premium of 2.9x vs Medical Devices peers. Elevated but may be justified by growth trajectory.
Momentum
Hot
+35.1% over 3m
Quality
Excellent
High-growth business (3% revenue growth, 64% gross margin). Profitable with strong growth momentum.
Dividend
None
No dividend
Smart-money signal
Who's buying BLFS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of $0.91 vs $0.03 consensus (+2812.0% surprise). Revenue of $28.5M vs $27.8M expected (+2.4%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+2812.0%
Revenue trend · last 8Q
—
-120%
+30%
+29%
-8%
—
+15%
+12%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$30.6M
-$3.4M
$23.9M
$25.4M
$28.1M
$18.8M
$27.5M
$28.5M
Margins · last 8Q
Gross
64.5%
Operating
6.0%
Profit
158.4%
Wall Street consensus
5 analysts · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
100%
Sell
0%
Median Price Target
—
Latest: Benchmark · Aug 10, 2026
vs Industry
How BLFS stacks vs Medical - Instruments & Supplies
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related